Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Harding, M., Cantwell, B., Milstead, R. et al. Phase II study of the thymidylate synthetase inhibitor CB3717 (N10-propargyl-5,8-dideazafolic acid) in colorectal cancer. Br J Cancer 57, 628–629 (1988). https://doi.org/10.1038/bjc.1988.143
Issue Date:
DOI: https://doi.org/10.1038/bjc.1988.143
- Springer Nature Limited
This article is cited by
-
From methotrexate to pemetrexed and beyond. A review of the pharmacodynamic and clinical properties of antifolates
Investigational New Drugs (2006)
-
TomudexTM (ZD1694): from concept to care, a programme in rational drug discovery
Investigational New Drugs (1996)
-
Biochemical effects of folate-based inhibitors of thymidylate synthase in MGH-U1 cells
Cancer Chemotherapy and Pharmacology (1994)